Otwarty dostęp

Semaphorin 5A as a Novel Diagnostic Biomarker of Juvenile Idiopathic Arthritis

Justyna Roszkiewicz

Justyna Roszkiewicz

Department of Pediatric Cardiology and Rheumatology, Medical University of LodzLodz, Poland
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Roszkiewicz, Justyna
, 
Krystyna Wyka

Krystyna Wyka

Department of Pediatrics Hematology and Oncology, Medical University of LodzLodz, Poland
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Wyka, Krystyna
 oraz 
Elżbieta Smolewska

Elżbieta Smolewska

Department of Pediatric Cardiology and Rheumatology, Medical University of LodzLodz, Poland
Profil Orcid
Wyszukaj tego autora
Sciendo|Google Scholar
Smolewska, Elżbieta
  
28 maj 2025
Semaphorin 5A as a Novel Diagnostic Biomarker of Juvenile Idiopathic Arthritis's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Pobierz okładkę
Kategoria artykułu: Original
Data publikacji: 28 maj 2025
Otrzymano: 07 gru 2024
Przyjęty: 13 mar 2025
DOI: https://doi.org/10.2478/aite-2025-0013
Słowa kluczowe
© 2025 Justyna Roszkiewicz et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig 1.

Concentration of serum SEMA5A in JIA patients and healthy controls. JIA, juvenile idiopathic arthritis; SEMA5A, semaphorin 5A.
Concentration of serum SEMA5A in JIA patients and healthy controls. JIA, juvenile idiopathic arthritis; SEMA5A, semaphorin 5A.

Fig 2.

SEMA5A promotes inflammation via different pathways. It increases the proliferation of T and NK cells, leading to higher secretion of proinflammatory cytokines. SEMA5A stimulation leads to activation of synovial fibroblasts by downregulating apoptosis via the PI3K/AKT/mTOR pathway. Moreover, it stimulates angiogenesis by increasing endothelial cell migration from preexisting vessels via activation of Met tyrosine kinases. Created using Biorender (www.biorender.com). AKT, protein kinase B; IFN, interferon; IL, interleukin; mTOR, mammalian target of rapamycin kinase; NK, natural killer; PI3K, phosphoinositide 3-kinase; SEMA5A, semaphorin 5A; TNF, tumor necrosis factor.
SEMA5A promotes inflammation via different pathways. It increases the proliferation of T and NK cells, leading to higher secretion of proinflammatory cytokines. SEMA5A stimulation leads to activation of synovial fibroblasts by downregulating apoptosis via the PI3K/AKT/mTOR pathway. Moreover, it stimulates angiogenesis by increasing endothelial cell migration from preexisting vessels via activation of Met tyrosine kinases. Created using Biorender (www.biorender.com). AKT, protein kinase B; IFN, interferon; IL, interleukin; mTOR, mammalian target of rapamycin kinase; NK, natural killer; PI3K, phosphoinositide 3-kinase; SEMA5A, semaphorin 5A; TNF, tumor necrosis factor.

Fig S1.

ROC for SEMA5A as a JIA diagnostic biomarker. JIA, juvenile idiopathic arthritis; ROC, receiver operating characteristic curve; SEMA5A, semaphorin 5A.
ROC for SEMA5A as a JIA diagnostic biomarker. JIA, juvenile idiopathic arthritis; ROC, receiver operating characteristic curve; SEMA5A, semaphorin 5A.

Clinical and laboratory characteristics of study and control groups

Characteristic Study group Control group p*value
Gender
Male (no.) 17 17 1.0
Female (no.) 17 17 1.0
Age (years) 9.75 (±4.85) 9.89 (±5.00) 0.9
Disease subtype
Oligoarticular (%) 50 n/a
Polyarticular seronegative (%) 11.8 n/a
Polyarticular seropositive (%) 8.8 n/a
ERA (%) 23.6 n/a
Psoriatic arthritis (%) 5.8 n/a
Median CRP value (mg/L) 12.5 0.4 <0.001
Median ESR value (mm/h) 34 4 <0.001
ANA positivity (%) 88.21 n/a
HLA-B27 positivity (%) 35.23 n/a
RF positivity (%) 8.82 n/a
Anti-CCP positivity (%) 5.88 n/a
Mean number of joints with active arthritis (no.) 3.29 n/a
Mean CHAQ value 0.45 n/a
Mean JADAS 71 value 14.12 n/a
Median/mean SEMA5A concentration (ng/mL) in all JIA 2.04 1.34 0.002
In oligoarticular JIA 1.76 (IQR 1.56) 0.33 (IQR 1.33) <0.001
In polyarticular seronegative JIA 2.57 (±1.58) 1.44 0.266
In polyarticular seropositive JIA 7.57 (±5.26) 1.61 (±0.54 ng/mL) 0.123
In ERA JIA 1.97 (IQR 1.67) 1.45 (IQR 1.31) 0.25
VEGF-A concentration (pg/mL) 352.69 (IQR 454.64) 163.13(IQR 154.54) <0.01
Język:
Angielski
Częstotliwość wydawania:
1 razy w roku
Dziedziny czasopisma:
Medycyna, Podstawowe nauki medyczne, Biochemia, Immunologia, Medycyna kliniczna, Medycyna kliniczna, inne, Chemia kliniczna
Kanał RSS czasopisma